| titleOfInvention |
COMPOUND; COMPOSITION; METHOD OF TREATMENT AND / OR PREVENTION OF MIGRAINE, ALS, ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, EXTRAPYRIMIDAL DISORDERS, DEPRESSION, NAUSEA, AEMESIS, SYNDROME OF THE WASTE LEGS, INSOMENESS, HYGERNESS, AGING , ANXIETY, DRUG DEPENDENCIES, DYSTONIA, PARASSONIA OR HYPERLACTINEMIA IN AN INDIVIDUAL; AGONIZATION METHODS OF D2, 5-HT1D, 5-HT1A AND 5-HT2C RECEPTORS, IN AN INDIVIDUAL; ANTAGONIZATION METHOD OF THE D3 RECEPTOR IN AN INDIVIDUAL; METHODS OF SELECTIVE AGONIZATION OF RECEPTORS 5 -HT1D, AND 5-HT2C, METHOD OF PROVIDING FUNCTIONAL ANTAGONIST ACTIVITY IN RECEPTOR 5 -HT2B OR IN RECEIVER 5-HT7, OR IN BOTH, IN AN INDIVIDUAL; METHOD OF PROVIDING FUNCTIONAL ANTAGONIST ACTIVITY IN ADRENERGIC RECEPTORS IN AN INDIVIDUAL |
| abstract |
ergoline compounds and pharmaceutical compositions thereof are provided, as well as the use of such compounds and pharmaceutical compositions in methods of treating, preventing or ameliorating a variety of medical disorders, such as migraine; receptor agonization methods, such as 5-ht1a, 5-ht1b and 5-ht1d receptors, without 5-ht2b receptor agonization; alpha2a and / or alpha2b adrenergic receptor antagonizing methods; and methods of d2 and d3 receptor antagonization. |